Center for Health Equity Research and Promotion
Yu-Xiao Yang, MD, MS
CHERP COIN Investigator
Staff Gastroenterologist, Philadelphia VA Medical Center
Associate Professor of Medicine and Epidemiology, University of Pennsylvania
Yu-Xiao Yang, MD, MSCE conducts pharmacoepidemiology research to improve the safety of acid-suppressive drug therapy, such as proton pump inhibitors. His research addresses the safety of chronic acid-suppressive therapy, which has profound implications for the approach to the medical management of acid-related GI conditions. He also examines the effect of growth factors (e.g., endogenous and exogenous insulin) on GI cancer risk. This issue has far-reaching implications for cancer prevention for the enormous population of diabetes patients.
He currently leads a VA Merit Award entitled The Effect of Exogenous Insulin Therapy on Colorectal Adenoma Risk among Patients with type 2 diabetes. This study will determine whether use of insulin therapy would increase the risk of colorectal adenoma recurrence among patients with type 2 diabetes mellitus. He is also interested in expanding his VA research to examine how proton pumps are prescribed in VHA, and how to improve patient care and outcomes. Besides the VA, his research program in pharmacoepidemiology and GI cancer epidemiology has also been funded by the NIH (R01, K08, P30), the AHRQ (R01), and GI foundations.
Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens (IIR 15-346) as Principal Investigator
- Safety of Acid-suppressive Drug Therapy